Meeting
2018 ASCO Annual Meeting
A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).
Authors
Araz Marachelian
Children's Hosp Los Angeles, Los Angeles, CA
Araz Marachelian , Judith Villablanca , Angela Duvalyan , Scarlett Czarnecki , Susan G. Groshen , Denice Tsao-Wei , Richard Sposto , Jemily Malvar , Jianping Sun , Kelly C. Goldsmith , Yael P. Mosse , Meaghan Granger , Nita Seibel , Jeffrey Moscow , Katherine K. Matthay , Michael Sheard , Robert Seeger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01711554
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10522)
DOI
10.1200/JCO.2018.36.15_suppl.10522
Abstract #
10522
Poster Bd #
195
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy: Results of 2 consecutive studies in a single referral institution.
First Author: Jaume Mora
Poster
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
First Author: Holger N. Lode
Poster
2022 ASCO Annual Meeting
Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
First Author: Thomas Cash
Poster
2024 ASCO Annual Meeting
Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma.
First Author: Feifei Sun